Coenzyme Q10 as a Symptomatic Treatment in Parkinson's Disease
Multicenter, Placebo Controlled, Randomized, Double-Blinded Study: Coenzyme Q10 Nanodispersion Versus Placebo as Symptomatic Treatment in Parkinson's Disease
Sponsor: Deutsche Parkinson-Vereinigung e.V.
A PHASE3 clinical study on Parkinson's Disease, this trial is completed. The trial is conducted by Deutsche Parkinson-Vereinigung e.V. and has accumulated 8 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Mar 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Feb 2025 — Mar 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Feb 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Sep 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Deutsche Parkinson-Vereinigung e.V.
- MSE Pharmazeutika GmbH, Bad Homburg
- Technische Universität Dresden
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Berlin, Germany , Bochum, Germany , Dresden, Germany , Essen, Germany , Hagen, Germany , Homburg, Germany , Ichenhausen, Germany , Lemgo, Germany , Lüneburg, Germany , Marburg, Germany and 3 more locations